Thursday, November 17, 2022
Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that the Centers for Medicare and Medicaid Services (CMS) assigned physician and facility payment for a new Category I Current Procedural Terminology (CPT®) code that includes the use of VivAer® to repair nasal valve collapse (NVC) when performed in the office and outpatient surgical settings. The new code goes into effect on January 1, 2023.
“Actions by the AMA and CMS to establish and implement this new Category I code are an important validation of treatment with VivAer as a unique and distinct therapy for the repair of NVC,” said Matt Brokaw, CEO of Aerin Medical. “We are excited about the potential for improved access for the ENT physician community and millions of nasal airway obstruction sufferers in the U.S.”
The new code was implemented and assigned a national payment rate as part of CMS’ Calendar Year (CY) 2023 Medicare Physician Fee Schedule Final Rule and its CY 2023 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Final Rule. CPT code 30469, repair of NVC with low energy, temperature-controlled (i.e., radiofrequency) subcutaneous/submucosal remodeling, was established by the American Medical Association (AMA) describing use of VivAer for this procedure. Because of the non-invasive nature of the treatment, the new code has been assigned a zero-day global period.
